In summary, our current study uses syngeneic melanoma mouse models to show that pharmacologic inhibition of PPARγ boosts anticancer immunotherapies in a sexually dimorphic and obesity-dependent manner. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.